⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825497 | 0.79 | — | — | |
| SCHEMBL28219308 | 0.77 | — | — | |
| SCHEMBL322299 | 0.76 | — | — | |
| SCHEMBL6814755 | 0.76 | L3MBTL1 (0.35) | — | |
| SCHEMBL1698587 | 0.74 | — | — | |
| SCHEMBL28754859 | 0.74 | — | — | |
| SCHEMBL28117867 | 0.72 | — | — | |
| SCHEMBL6376109 | 0.72 | L3MBTL1 (0.33) | — | |
| SCHEMBL28141287 | 0.72 | — | — | |
| SCHEMBL7782987 | 0.70 | SMN1; SMN2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627639-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051551-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | WO | claimed |
| EP-2627639-B1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10265411-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180140712-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2018-05-24 | — | — | US | disclosed |
| US-9907855-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170165372-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2017-06-15 | — | — | US | disclosed |
| US-9616136-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160144047-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9226971-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140296334-A1 | N-Optionally Substituted Aryl-2-Oligomer-3-Alkoxypropionamides | NEKTAR THERAPEUTICS | 2014-10-02 | — | — | US | disclosed |
| EP-2627639-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051551-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | WO | disclosed |